Fate Therapeutics Inc
FATE
Company Profile
Business description
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Contact
12278 Scripps Summit Drive
San DiegoCA92131
USAT: +1 858 875-1800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
181
Stocks News & Analysis
stocks
Signs of a turnaround for undervalued ASX share
Market likes the payoff from early efforts at reining in costs.
stocks
Australia has the highest dividend yields in the world, so why the endless chase for even higher yields?
Ashley Owen explores why investors' insatiable thirst for higher yields leads to unnecessarily complicating their portfolio.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,825.10 | 20.90 | 0.24% |
| CAC 40 | 8,178.54 | 14.43 | 0.18% |
| DAX 40 | 22,513.42 | 98.60 | -0.44% |
| Dow JONES (US) | 44,546.08 | 165.35 | -0.37% |
| FTSE 100 | 8,732.46 | 32.26 | -0.37% |
| HKSE | 22,620.33 | 805.96 | 3.69% |
| NASDAQ | 20,026.77 | 81.13 | 0.41% |
| Nikkei 225 | 39,149.43 | 312.04 | -0.79% |
| NZX 50 Index | 12,989.18 | 83.20 | 0.64% |
| S&P 500 | 6,114.63 | 0.44 | -0.01% |
| S&P/ASX 200 | 8,555.80 | 15.80 | 0.19% |
| SSE Composite Index | 3,346.72 | 14.24 | 0.43% |